Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH) (ANTI-FLUSH)
Advancing Niacin by Inhibiting FLUSHing: (ANTI-FLUSH)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Phila, Pennsylvania, United States, 19104
- CTRC Univ. of Penn - Andrew Mutch Bldg., 4th floor
-
Phila, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women from the age of 21 to 75, inclusive - 16 subjects, 8 men, 8 women.
- Ability to understand and agree to informed consent.
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
Exclusion Criteria:
- Contra-indications or known intolerance to the study medications.
- History of congestive heart failure, carcinoid, rosacea, renal failure (GFR<60 ml/min/m2).
- Active liver disease.
- Active diabetes (defined as any history of type 1 diabetes, or history of type 2 diabetes plus one or more of the following: fasting glucose>= 126mg/dL at screening or use of anti-diabetic medications within 12 months, or glucose>200mg/dL 2 hours after a 75 g oral glucose challenge within 12 months.
- History of major surgery within the past 6 weeks, or anticipated major surgery during the course of the study, or any history of organ transplant.
- History of drug abuse within the past 3 years, or regular alcohol use of greater than 14 drinks per week.
- Women who are pregnant, plan to conceive or lactate.
- Peri-menopausal women or women currently experiencing flushing.
- Currently taking vasoactive medications, anti-hypertensives, anti-histamines, Selective Serotonin Re-uptake Inhibitors (SSRIs), NSAIDS, oral steroids, leukotriene inhibitors, supplemental quercetin and > 50mg niacin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Quercetin 500 mg
Quercetin 500 mg once, administered one hour before 500 mg immediate-release niacin
|
Quercetin 500, 1000, or 2000 mg PO one time
Other Names:
|
|
Experimental: Quercetin 1000 mg
Quercetin 1000 mg once, administered one hour before 500 mg immediate-release niacin
|
Quercetin 500, 1000, or 2000 mg PO one time
Other Names:
|
|
Experimental: Quercetin 2000 mg
Quercetin 2000 mg once, administered one hour before 500 mg immediate-release niacin
|
Quercetin 500, 1000, or 2000 mg PO one time
Other Names:
|
|
Placebo Comparator: Placebo
Placebo once, administered one hour before 500 mg immediate-release niacin
|
Placebo PO one time
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Whether Quercetin Dose-dependently Reduces Laser Doppler Flux Index Primary Peak Following Immediate-release Niacin
Time Frame: 8 hour period
|
Laser Doppler flowmetry at the malar eminence measures blood flow quantitatively as red blood cell flux.
Flux index is the fold-change in flux over baseline.
Flux index primary peak is the maximum flux index between 0-4 hours after niacin.
|
8 hour period
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Richard L. Dunbar, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB #808911
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.